English
realiable etizolam etizolam powder china supplier etizolam
Product Details
| Place of Origin: | China |
|---|---|
| Brand Name: | |
| Certification: | ISO，CE |
| Model Number: |
Payment Terms
| Min.Order Quantity: | 10 Grams |
|---|---|
| Price: | USD $100 - $200 / Gram |
| Payment Terms: | D/A,Western Union |
Product Description
Introduction
Name:Etizolam
Accession Number:DB09166
Type:Small Molecule
Groups:Experimental
Description
Etizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class;
it differs from BDZs in having a benzene ring replaced with a thiophene ring.
It is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.
Indication
Indicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.
Etizolam vs. Xanax: What's the Difference? What You Need to
Etizolam is primarily used to treat insomnia and anxiety disorders, and it's especially good at relieving anxiety. But it's less likely to have hypnotic effects. In higher doses, it can cause hypnosis, sedation, loss of motor control, and other effects consistent with sleep aids
Etizolam - Wikipedia
Etizolam (marketed under many brand names) is a thienodiazepine derivative which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring and triazole ring has been fused, making the drug a thienotriazolodiazepine
A case of etizolam dependence - NCBI
[1] Etizolam is a thienodiazepine anxiolytic and is said to have low tolerance and dependence liability than benzodiazepines.[2] We report a case of etizolam
Etizolam | Effects of Etizolam | FRANK
Etizolam. Also called: Zoly; Sylazepam; Pasaden; Mozun; Inxity; Etizola; Etisedan; Etilaam; Eticalm; Dezolam; Depas
Information Sheet Etizolam - Scottish Drugs Forum
Drug overview: Etizolam is a benzodiazepine analogue, a thienodiazepene.1 It has gathered some popularity on the new psychoactive substance (NPS) market